Диссертация (1139510), страница 56
Текст из файла (страница 56)
Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation ofpsychotropic medications in Australia from 2000 to 2011. Aust N Z JPsychiatry. 2013;47:74–87. doi: 10.1177/0004867412466595.343. Strawbridge et al. Biomarkers for depression: recent insights, currentchallenges and future prospects. Neuropsychiatric Disease and Treatment 2017:131245–1262.344. Sychev DA, Shuev GN, Suleymanov SS, et al. Comparisonof CYP2C9, CYP2C19, CYP2D6, ABCB1,and SLCO1B1 gene-polymorphismfrequency in Russian and Nanai populations. Pharmgenomics Pers Med.2017;10:93-99.
Published 2017 Mar 31. doi:10.2147/PGPM.S129665345. TableofPharmacogenomicBiomarkersinDrugLabeling.http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm346. Tai YH, Tsai RY, Lin SL, et al.Amitriptyline suppressesneuroinflammation-dependent interleukin-10-p38 mitogen-activated protein295kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats.Anesthesiology. 2009 Jun;110(6):1379-89.347. Takayanagi Y, Spira AP, Bienvenu OJ, et al. Antidepressant use and lifetimehistory of mental disorders in a community sample: results from the BaltimoreEpidemiologic Catchment Area Study.
J Clin Psychiatry. 2015;76(1):40-4.348. Tan YW, Zhang SJ, Hoffmann T, Bading H. Increasing levels of wild-typeCREB up-regulates several activity-regulated inhibitor of death (AID) genes andpromotes neuronal survival. BMC Neurosci. 2012 May 18;13:48.349. ten Doesschate MC, Bockting CL, Koeter MW et al. Predictors ofnonadherence to continuation and maintenance antidepressant medication inpatients with remitted recurrent depression. J Clin Psychiatry 2009;70:63–9.350. ten Doesschate MC, Bockting CL, Schene AH.
Adherence to continuationandmaintenanceantidepressantuseinrecurrentdepression. JAffectDisord 2009;115:167–70.351. Trivedi M.H. Right patient, right treatment, right time: biosignatures andprecision medicine in depression World Psychiatry 15:3 - October 2016 pp. 237238.352. Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes withcitalopram for depression using measurement-based care in STAR*D: implicationsfor clinical practice.
Am J Psychiatry. 2006 Jan;163(1):28-40.353. Turner EH, Matthews AM, Linardatos, E, Tell RA, Rosenthal R: Selectivepublication of antidepressant trials and its influence on apparent efficacy. N Engl JMed 2008;358:252–260.354. Tylee A, Walters P. Underrecognition of anxiety and mood disorders inprimary care: why does the problem exist and what can be done? J Clin Psychiatry.2007;68 Suppl 2:27–30.355. Uher R, Muthén B, Souery D, Mors O, Jaracz J, Placentino A, Petrovic A,Zobel A, Henigsberg N, Rietschel M, Aitchison KJ, Farmer A, McGuffin P:Trajectories of change in depression severity during treatment with antidepressants.Psychol Med 2010, 40:1367-1377.356.
Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, et al.Depression symptom dimensions as predictors of antidepressant treatmentoutcome: replicable evidence for interest-activity symptoms. Psychol Med.2011;42:967–80.357. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T,Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, SpechtM, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F. Polymorphisms in the drugtransporter gene ABCB1 predict antidepressant treatment response in depression.296Neuron. 2008 Jan 24;57(2):203-9.358. van Loo HM, de Jonge P et al. Data-driven subtypes of major depressivedisorder: a systematic review.
BMC Medicine 2012, 10:156.359. van Loo, H. M. (2015). Data-driven subtypes of major depressive disorder.[Groningen]: University of Groningen360. Van Praag, H. M. (2008). Kraepelin, biological psychiatry, and beyond.European Archives of Psychiatry and Clinical Neuroscience, 258(S2), 29–32.361. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs)for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysisfor the Global Burden of Disease Study 2010. Lancet 2012;380:2163–96.362.
Vose, L. R., and Stanton, P. K. (2017). Synaptic plasticity, metaplasticity anddepression. Curr. Neuropharmacol. 15, 71–86.363. Wakefield J.C. Wittgenstein’s nightmare: why the RDoC grid needs aconceptual dimension // World Psychiatry. 2014. Vol. 13. P. 38–39.364. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W.
CommonCYP2D6 polymorphisms affecting alternative splicing and transcription: longrange haplotypes with two regulatory variants modulate CYP2D6 activity. HumMol Genet. 2014 Jan 1;23(1):268-78.365. Wichers M, Groot P, Simons CJP et al. Critical slowing down as apersonalized early warning signal for depression. Psychother Psychosom 2016;85:114-6.366. Wray NR, Pergadia ML, Blackwood DHR, Penninx BWJH, Gordon SD,Nyholt DR, et al. Genome-wide association study of major depressive disorder:new results, meta-analysis, and lessons learned.
Mol Psychiatry. 2012;17:36–48.367. Xia Z, DePierre JW, Nassberger L: Tricyclic antidepressants inhibit IL-6, IL1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferongamma in T cells. Immunopharmacology 1996; 34:27–37.368. Yamauchi M, Takako M, Tetsuya M, et al. Desensitization of 5-HT2Areceptor function by chronic administration of selective serotonin reuptakeinhibitors. Brain Res 2005;1067:164-9.369.
Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter genelinked polymorphic region on the antidepressant response to fluvoxamine inJapanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry.2002;26:383–6.370. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressantresponse to milnacipran by norepinephrine transporter gene polymorphisms. Am JPsychiatry. 2004;161:1575–80.371. Yoshimura R, Umene-Nakano W, Suzuki A, et al. Rapid response to297paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks oftreatment, and is independent of serotonin transporter promoter polymorphism inJapanese depressed patients.
Hum Psychopharmacol. 2009;24:489–94372. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overviewand update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs ArchPharmacol. 2004;369(1):23–37.373. Zimmerman M, Posternak M, Friedman M et al. Which factors influencepsychiatrists' selection of antidepressants? Am J Psychiatry 2004;161:1285-9.374. Zullino D , Baumann P . 2001 . Lithium augmentation in depressive patientsnot responding to selective serotonin reuptake inhibitors .
Pharmacopsychiatry 34 :119 – 127.298.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
